September 8, 2023
Kenporen Director Masato Matsumoto Nearly 90% of the top 100 high-cost monthly medical bills received by the National Federation of Health Insurance Societies (Kenporen) in FY2022 were for four pricey cell and gene therapy products rolled out in Japan in...read more